Corporate calendar for Annovis Bio, Inc. (ANVS): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | $159M | |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | ||
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 |
Price
| Price | $1.04 |
| Market Cap | $44M |
| Exchange | NYSE |
| Country | US |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.75 |
Related companies: ATNM · BCAB · BTAI · CELU · ELUT · EVAX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of ANVS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks